Progression in patients on first-line imatinib.
| Year . | Progression* (%) . | Progression to Accelerated Phase or Blast Crisis (%) . |
|---|---|---|
| * Includes loss of complete hematologic response (CHR), loss of major cytogenetic response (MCR), and progression to accelerated phase and blast crisis. | ||
| 1 | 3.4 | 1.5 |
| 2 | 7.5 | 2.8 |
| 3 | 4.6 | 1.6 |
| 4 | 2.3 | 2.2 |
| mean | 4.0 | 2.0 |
| Year . | Progression* (%) . | Progression to Accelerated Phase or Blast Crisis (%) . |
|---|---|---|
| * Includes loss of complete hematologic response (CHR), loss of major cytogenetic response (MCR), and progression to accelerated phase and blast crisis. | ||
| 1 | 3.4 | 1.5 |
| 2 | 7.5 | 2.8 |
| 3 | 4.6 | 1.6 |
| 4 | 2.3 | 2.2 |
| mean | 4.0 | 2.0 |